To go or not to go? Biological logic gating engineered T cells
- Author(s)
- Abbott, RC; Hughes-Parry, HE; Jenkins, MR;
- Details
- Publication Year 2022-04,Volume 10,Issue #4,Page e004185
- Journal Title
- Journal for Immunotherapy of Cancer
- Abstract
- Genetically engineered T cells have been successfully used in the treatment of hematological malignancies, greatly increasing both progression-free and overall survival in patients. However, the outcomes of patients treated with Chimeric Antigen Receptor (CAR) T cells targeting solid tumors have been disappointing. There is an unmet clinical need for therapies which are specifically designed to overcome the challenges associated with solid tumors such as tumor heterogeneity and antigen escape. Genetic engineering employing the use of biological logic gating in T cells is an emerging and cutting-edge field that may address these issues. The advantages of logic gating include localized secretion of anti-tumor proteins into the tumor microenvironment, multi antigen targeting of tumors and a potential increase in safety when targeting tumor antigens which may not be exclusively tumor specific. In this review, we introduce the concept of biological logic gating and how this technology addresses some of the challenges of current CAR T treatment. We outline the types of logic gating circuits and finally discuss the application of this new technology to engineered T cells, in the treatment of cancer.
- Publisher
- BMJ
- Keywords
- Humans; Logic; *Neoplasms/therapy; Receptors, Antigen, T-Cell; *T-Lymphocytes; Tumor Microenvironment; cell engineering; cytotoxicity, immunologic; immunotherapy; receptors, chimeric antigen
- Research Division(s)
- Immunology
- PubMed ID
- 35379738
- Publisher's Version
- https://doi.org/10.1136/jitc-2021-004185
- Open Access at Publisher's Site
https://doi.org/10.1136/jitc-2021-004185- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2022-04-08 10:53:22
Last Modified: 2022-04-08 10:56:26